Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
MSD and Taiho Pharmaceutical will terminate their copromotion deal for the US giant’s anti-PD-1 antibody Keytruda (pembrolizumab) at the end of December, putting an end to nearly three years of their collaboration as the drug enjoys strong market penetration in…
To read the full story
Related Article
- MSD Picks Taiho as Copromotion Partner for Pembrolizumab
April 12, 2016
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





